Recent advances in oxazolidinones as antituberculosis agents

Area of Science:

• Medicinal Chemistry
• Microbiology
• Pharmacology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a significant global health threat.
• Developing novel antitubercular agents is essential for the World Health Organization's End TB strategy.
• Oxazolidinones are synthetic antibacterials effective against Gram-positive bacteria.

Purpose of the Study:

• To review the mechanism of action, activity, and toxicity of oxazolidinones.
• To summarize recent advancements in oxazolidinone research for TB treatment.
• To highlight the potential of oxazolidinones in combating drug-resistant TB.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of oxazolidinone's mode of action against Mtb.
• Evaluation of reported activity and toxicity profiles.

Main Results:

• Oxazolidinones possess a distinct mechanism of action against bacterial protein synthesis.
• Several oxazolidinones demonstrate significant in vitro and in vivo activity against Mtb.
• Some oxazolidinones are progressing through clinical trials for multidrug-resistant and extensively drug-resistant TB.

Conclusions:

• Oxazolidinones represent a promising class of compounds for novel anti-TB drug development.
• Further research and clinical evaluation are warranted to establish their role in TB therapy.
• These agents offer potential therapeutic options for challenging TB infections.